The long noncoding RNA FTH1P3 promotes the proliferation and metastasis of cervical cancer through microRNA‑145

Lv,Rui; Zhang,Qian   Wen

doi:10.3892/or.2019.7413

The long noncoding RNA FTH1P3 promotes the proliferation and metastasis of cervical cancer through microRNA‑145

Authors:
- Rui Lv
- Qian Wen Zhang
View Affiliations

Affiliations: Department of Gynecological Oncology Ward, Gansu Provincial Cancer Hospital, Lanzhou, Gansu 730050, P.R. China
Published online on: November 20, 2019 https://doi.org/10.3892/or.2019.7413
Pages: 31-40
Copyright: © Lv et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Emerging evidence has revealed that long noncoding RNAs (lncRNAs) play crucial roles in the development and progression of tumors. The present study aimed to examine the roles and illustrate the underlying mechanisms of lncRNA ferritin heavy chain 1 pseudogene 3 (FTH1P3) in cervical cancer. The expression of lncRNA FTH1P3 and microRNA‑145 (miRNA‑145 or miR‑145) in human cervical cancer samples and cervical cancer cell lines was detected by qRT‑PCR (reverse transcription‑quantitative polymerase chain reaction). FTH1P3 overexpression, siRNA plasmid, hsa‑miR‑145 mimic or hsa‑miR‑145 inhibitor were transfected. The target of FTH1P3 was predicted by bioinformatics analysis and validated by luciferase assay. Statistical significance analysis was performed by SPSS software. The results revealed that FTH1P3 was significantly upregulated in cervical cancer tissues compared with normal tissues. Increased expression of FTH1P3 was revealed in human cervical cancer cell lines compared with cervical normal epithelial cells. Downregulation of FTH1P3 inhibited cell proliferation, invasion and migration, and promoted apoptosis in cervical cancer cells. miR‑145 was predicted and validated as a direct target of FTH1P3. Moreover, FTH1P3 siRNA partially attenuated the effects of the miR‑145 inhibitor on cell viability and mobility in cervical cancer cells. The present results demonstrated that lncRNA FTH1P3 functioned as a promoting factor in cervical cancer by targeting miR‑145.

View Figures

View References

1	Zeferino LC and Derchain SF: Cervical cancer in the developing world. Best Pract Res Clin Obstet Gynaecol. 20:339–354. 2006. View Article : Google Scholar : PubMed/NCBI
2	Ohazurike E, Anorlu I, Okunade K, Okunowo A and Sajo A: Cervical cancer: An urgent need to scale up screening in the developing world. Int J Gynecol Cancer. 27:842. 2017.
3	Nogueira-Rodrigues A, de Melo AC, Garces AHI, Paulino E, Alves FV, Vilaça Mdo N, Silva LG, Gonçalves CA, Fabrini JC, Carneiro AT and Thuler LC: Patterns of care and outcome of elderly women diagnosed with cervical cancer in the developing world. Int J Gynecol Cancer. 26:1246–1251. 2016. View Article : Google Scholar : PubMed/NCBI
4	Rao GG, Rogers P, Drake RD, Nguyen P and Coleman RL: Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol. 96:168–172. 2005. View Article : Google Scholar : PubMed/NCBI
5	Falcetta FS, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT and Rosa DD: Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev. 11:CD0053422016.PubMed/NCBI
6	Rosa DD, Medeiros LR, Edelweiss MI, Bozzetti MC, Pohlmann PR, Stein AT and Dickinson HO: Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev. CD0053422009.PubMed/NCBI
7	Rosa DD, Medeiros LR, Edelweiss MI, Pohlmann PR and Stein AT: Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev. CD0053422012.PubMed/NCBI
8	Kung JT, Colognori D and Lee JT: Long noncoding RNAs: Past, present, and future. Genetics. 193:651–669. 2013. View Article : Google Scholar : PubMed/NCBI
9	Jin XJ, Chen XJ, Hu Y, Ying F, Zou R, Lin F, Shi Z, Zhu X, Yan X, Li S and Zhu H: LncRNA-TCONS_00026907 is involved in the progression and prognosis of cervical cancer through inhibiting miR-143-5p. Cancer Med. 6:1409–1423. 2017. View Article : Google Scholar : PubMed/NCBI
10	Zhang J, Yao T, Wang Y, Yu J, Liu Y and Lin Z: Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biol Ther. 17:104–113. 2016. View Article : Google Scholar : PubMed/NCBI
11	Jiang Y, Li Y, Fang S, Jiang B, Qin C, Xie P, Zhou G and Li G: The role of MALAT1 correlates with HPV in cervical cancer. Oncol Lett. 7:2135–2141. 2014. View Article : Google Scholar : PubMed/NCBI
12	Di Sanzo M, Aversa I, Santamaria G, Gagliardi M, Panebianco M, Biamonte F, Zolea F, Faniello MC, Cuda G and Costanzo F: FTH1P3, a Novel H-Ferritin pseudogene transcriptionally active, is ubiquitously expressed and regulated during cell differentiation. PLoS One. 11:e01513592016. View Article : Google Scholar : PubMed/NCBI
13	Zhang CZ: Long non-coding RNA FTH1P3 facilitates oral squamous cell carcinoma progression by acting as a molecular sponge of miR-224-5p to modulate fizzled 5 expression. Gene. 607:47–55. 2017. View Article : Google Scholar : PubMed/NCBI
14	Zovoilis A, Mungall AJ, Moore R, Varhol R, Chu A, Wong T, Marra M and Jones SJ: The expression level of small non-coding RNAs derived from the first exon of protein-coding genes is predictive of cancer status. EMBO Rep. 15:402–410. 2014. View Article : Google Scholar : PubMed/NCBI
15	Chaudhry MA: Expression pattern of small nucleolar RNA host genes and long non-coding RNA in X-rays-treated lymphoblastoid cells. Int J Mol Sci. 14:9099–9110. 2013. View Article : Google Scholar : PubMed/NCBI
16	Aalto AP and Pasquinelli AE: Small non-coding RNAs mount a silent revolution in gene expression. Curr Opin Cell Biol. 24:333–340. 2012. View Article : Google Scholar : PubMed/NCBI
17	Braconi C, Henry JC, Kogure T, Schmittgen T and Patel T: The role of MicroRNAs in human liver cancers. Semin Oncol. 38:752–763. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wilmott JS, Zhang XD, Hersey P and Scolyer RA: The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology. 43:657–671. 2011. View Article : Google Scholar : PubMed/NCBI
19	Esquela-Kerscher A: From worms to humans: Understanding the role of microRNAs in cancer progression. Cancer Res. 70:LB–353. 2010.
20	Gozuacik D, Akkoc Y, Ozturk DG and Kocak M: Autophagy- regulating microRNAs and cancer. Front Oncol. 7:652017. View Article : Google Scholar : PubMed/NCBI
21	Chu R, Mo GQ, Duan Z, Huang M, Chang J, Li X and Liu P: miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. Cell Commun Signal. 12:452014. View Article : Google Scholar : PubMed/NCBI
22	Ahmad MK, Waseem M, Serajuddin M, Mahdi AA, Sankhwar SN and Mishra DP: MicroRNA: A new potential marker for prostate cancer. Cancer Med. 7:17. 2018.
23	Hironaka-Mitsuhashi A, Matsuzaki J, Takahashi RU, Yoshida M, Nezu Y, Yamamoto Y, Shiino S, Kinoshita T, Ushijima T, Hiraoka N, et al: A tissue microRNA signature that predicts breast cancer recurrence in young women. PLoS One. 12:e01876382017. View Article : Google Scholar : PubMed/NCBI
24	Baldassari F, Zerbinati C, Galasso M, Corrà F, Minotti L, Agnoletto C, Previati M, Croce CM and Volinia S: Screen for MicroRNA and Drug interactions in breast cancer cell lines points to miR-126 as a modulator of CDK4/6 and PIK3CA inhibitors. Front Genet. 9:1742018. View Article : Google Scholar : PubMed/NCBI
25	Frixa T, Sacconi A, Cioce M, Roscilli G, Ferrara FF, Aurisicchio L, Pulito C, Telera S, Carosi M, Muti P, et al: MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration. Carcinogenesis. 39:293–304. 2018. View Article : Google Scholar : PubMed/NCBI
26	Heydari N, Nikbakhsh N, Sadeghi F, Farnoush N, Khafri S, Bastami M and Parsian H: Overexpression of serum MicroRNA-140-3p in premenopausal women with newly diagnosed breast cancer. Gene. 655:25–29. 2018. View Article : Google Scholar : PubMed/NCBI
27	Jiang SB, He XJ, Xia YJ, Hu WJ, Luo JG, Zhang J and Tao HQ: MicroRNA-145-5p inhibits gastric cancer invasiveness through targeting N-cadherin and ZEB2 to suppress epithelial-mesenchymal transition. Oncotargets Ther. 9:2305–2315. 2016.
28	Noh JH, Chang YG, Kim MG, Jung KH, Kim JK, Bae HJ, Eun JW, Shen Q, Kim SJ, Kwon SH, et al: MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett. 335:455–462. 2013. View Article : Google Scholar : PubMed/NCBI
29	Ding Y, Zhang C, Zhang J, Zhang N, Li T, Fang J, Zhang Y, Zuo F, Tao Z, Tang S, et al: miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-β1 expression. Int J Oncol. 50:1701–1710. 2017. View Article : Google Scholar : PubMed/NCBI
30	Wang M, Wang J, Deng J, Li X, Long W and Chang Y: MiR-145 acts as a metastasis suppressor by targeting metadherin in lung cancer. Med Oncol. 32:3442015. View Article : Google Scholar : PubMed/NCBI
31	Azizmohammadi S, Safari A, Azizmohammadi S, Kaghazian M, Sadrkhanlo M, Yahaghi E, Farshgar R and Seifoleslami M: Molecular identification of miR-145 and miR-9 expression level as prognostic biomarkers for early-stage cervical cancer detection. QJM. 110:11–15. 2017. View Article : Google Scholar : PubMed/NCBI
32	Zhou X, Yue Y, Wang R, Gong B and Duan Z: MicroRNA-145 inhibits tumorigenesis and invasion of cervical cancer stem cells. Int J Oncol. 50:853–862. 2017. View Article : Google Scholar : PubMed/NCBI
33	Sathyanarayanan A, Chandrasekaran KS and Karunagaran D: microRNA-145 downregulates SIP1-expression but differentially regulates proliferation, migration, invasion and Wnt signaling in SW480 and SW620 cells. J Cell Biochem. 119:2022–2035. 2018. View Article : Google Scholar : PubMed/NCBI
34	Zheng X, Tang H, Zhao X, Sun Y, Jiang Y and Liu Y: Long non-coding RNA FTH1P3 facilitates uveal melanoma cell growth and invasion through miR-224-5p. PLoS One. 12:e01847462017. View Article : Google Scholar : PubMed/NCBI
35	Wang R, Zhang T, Yang Z, Jiang C and Seng J: Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. J Cell Mol Med. 22:4068–4075. 2018. View Article : Google Scholar : PubMed/NCBI
36	Li C, Lu L, Feng B, Zhang K, Han S, Hou D, Chen L, Chu X and Wang R: The lincRNA-ROR/miR-145 axis promotes invasion and metastasis in hepatocellular carcinoma via induction of epithelial-mesenchymal transition by targeting ZEB2. Sci Rep. 7:46372017. View Article : Google Scholar : PubMed/NCBI
37	Mak IW, Singh S, Turcotte R and Ghert M: The epigenetic regulation of SOX9 by miR-145 in human chondrosarcoma. J Cell Biochem. 116:37–44. 2015. View Article : Google Scholar : PubMed/NCBI
38	Kou B, Gao Y, Du C, Shi Q, Xu S, Wang CQ, Wang X, He D and Guo P: miR-145 inhibits invasion of bladder cancer cells by targeting PAK1. Urol Oncol. 32:846–854. 2014. View Article : Google Scholar : PubMed/NCBI
39	Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L and Jiang BH: MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 40:761–774. 2012. View Article : Google Scholar : PubMed/NCBI
40	Qin J, Wang F, Jiang H, Xu J, Jiang Y and Wang Z: MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells. Int J Clin Exp Patho. 8:1328–1340. 2015.
41	Zhang X, Dong Y, Ti H, Zhao J, Wang Y, Li T and Zhang B: Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas. Hum Pathol. 44:2571–2580. 2013. View Article : Google Scholar : PubMed/NCBI